IDH3A and glioblastoma: Finally, given the absence of information regarding molecular subtypes within the UKBB cohort, the selection of GBM cases based on isocitrate dehydrogenase-wildtype as reported by the most recent WHO classification of CNS tumours (5th edition, 2021) was not possible because of the lack of this information in UKBB.